FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048285912> ?p ?o ?g. }

• W2048285912 endingPage "1233" @default.
• W2048285912 startingPage "1224" @default.
• W2048285912 abstract "The dimeric transmembrane integrin, α(v)β(3), is a well-investigated target by different imaging modalities through suitably labeled arginine-glycine-aspartic acid (RGD) containing peptides. In this study, we labeled four cyclic RGD peptides with or without PEG functional groups: c(RGDfK) (denoted as FK), PEG(3)-c(RGDfK) (denoted as FK-PEG(3)), E[c(RGDfK)](2) (denoted as [FK](2)), and PEG(4)-E[PEG(4)-c(RGDfK)](2) (denoted as [FK](2)-3PEG(4)), with (89)Zr (t(1/2) = 78.4 h), using the chelator desferrioxamine-p-SCN (Df) for imaging tumor integrin α(v)β(3).The Df conjugated RGD peptides were subjected to integrin α(v)β(3) binding assay in vitro using MDA-MB-435 breast cancer cells. The (89)Zr-labeled RGD peptides were then subjected to small animal positron emission tomography (PET) and direct tissue sampling biodistribution studies in an orthotopic MDA-MB-435 breast cancer xenograft model.All four tracers, (89)Zr-Df-FK, (89)Zr-Df-FK-PEG(3), (89)Zr-Df-[FK](2), and (89)Zr-Df-[FK](2)-3PEG(4), were labeled in high radiochemical yield (89 ± 4%) and high specific activity (4.07-6 MBq/μg). Competitive binding assay with (125)I-echistatin showed that conjugation of the RGD peptides to the Df chelator did not have significant impact on their integrin α(v)β(3) binding affinity and the dimeric peptides were shown to be more potent than the monomers. In agreement with binding results, tumor uptake of (89)Zr-Df-[FK](2) and (89)Zr-Df-[FK](2)-3PEG(4) was significantly higher (4.32 ± 1.73%ID/g and 4.72 ± 0.66%ID/g, respectively, at 2 h post-injection) than the monomers (89)Zr-Df-FK and (89)Zr-Df-FK-PEG(3) (1.97 ± 0.38%ID/g and 1.57 ± 0.49%ID/g, respectively, at 2 h post-injection). Out of the four labeled peptides, (89)Zr-Df-[FK](2)-3PEG(4) gave the highest tumor-to-background ratio (18.21 ± 2.52 at 2 h post-injection and 19.69 ± 3.99 at 4 h post-injection), with the lowest uptake in metabolic organs. Analysis of late time points biodistribution data revealed that the uptake in the tumor was decreased, along with increase in the bone, which implies decomplexation of (89)Zr-Df.Efficient radiolabeling of peptides with an appropriate chelator such as Df-RGD with (89)Zr was observed. The (89)Zr radiolabeled peptides provided high-quality and high-resolution microPET images in xenograft models. (89)Zr-Df-[FK](2)-3PEG(4) demonstrated the highest tumor-to-background ratio of the compounds tested. Preparation of (89)Zr peptides to take advantage of the longer half-life is unwarranted due to the relatively rapid clearance from the tumor region of peptide tracers prepared for this study and the increased uptake in the bone of transchelated (89)Zr with time (2.0 ± 0.36%ID/g, 24 h post-injection)." @default.
• W2048285912 created "2016-06-24" @default.
• W2048285912 creator A5000979147 @default.
• W2048285912 creator A5013254367 @default.
• W2048285912 creator A5013987568 @default.
• W2048285912 creator A5018249388 @default.
• W2048285912 creator A5032363862 @default.
• W2048285912 creator A5036820615 @default.
• W2048285912 creator A5040979952 @default.
• W2048285912 creator A5053879558 @default.
• W2048285912 creator A5078781359 @default.
• W2048285912 creator A5088055918 @default.
• W2048285912 creator A5089833045 @default.
• W2048285912 date "2010-12-16" @default.
• W2048285912 modified "2023-09-25" @default.
• W2048285912 title "MicroPET Imaging of Integrin αvβ3 Expressing Tumors Using 89Zr-RGD Peptides" @default.
• W2048285912 cites W1495287184 @default.
• W2048285912 cites W1573363574 @default.
• W2048285912 cites W1965384612 @default.
• W2048285912 cites W1973951040 @default.
• W2048285912 cites W1986676428 @default.
• W2048285912 cites W1990036692 @default.
• W2048285912 cites W1996489028 @default.
• W2048285912 cites W2000799481 @default.
• W2048285912 cites W2001753204 @default.
• W2048285912 cites W2016618261 @default.
• W2048285912 cites W2018159680 @default.
• W2048285912 cites W2029773366 @default.
• W2048285912 cites W2040573057 @default.
• W2048285912 cites W2048490035 @default.
• W2048285912 cites W2048598450 @default.
• W2048285912 cites W2058418451 @default.
• W2048285912 cites W2062437832 @default.
• W2048285912 cites W2065246138 @default.
• W2048285912 cites W2069422722 @default.
• W2048285912 cites W2080656565 @default.
• W2048285912 cites W2083916521 @default.
• W2048285912 cites W2084238159 @default.
• W2048285912 cites W2085607173 @default.
• W2048285912 cites W2102158108 @default.
• W2048285912 cites W2115269770 @default.
• W2048285912 cites W2122767481 @default.
• W2048285912 cites W2132689499 @default.
• W2048285912 cites W2136209423 @default.
• W2048285912 cites W2139367713 @default.
• W2048285912 cites W2148854468 @default.
• W2048285912 cites W2150228337 @default.
• W2048285912 cites W2155707671 @default.
• W2048285912 cites W2155827928 @default.
• W2048285912 cites W2162112703 @default.
• W2048285912 cites W2163158081 @default.
• W2048285912 cites W2163180789 @default.
• W2048285912 cites W2461642981 @default.
• W2048285912 cites W4240248079 @default.
• W2048285912 doi "https://doi.org/10.1007/s11307-010-0458-y" @default.
• W2048285912 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3137711" @default.
• W2048285912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21161690" @default.
• W2048285912 hasPublicationYear "2010" @default.
• W2048285912 type Work @default.
• W2048285912 sameAs 2048285912 @default.
• W2048285912 citedByCount "48" @default.
• W2048285912 countsByYear W20482859122012 @default.
• W2048285912 countsByYear W20482859122013 @default.
• W2048285912 countsByYear W20482859122014 @default.
• W2048285912 countsByYear W20482859122015 @default.
• W2048285912 countsByYear W20482859122016 @default.
• W2048285912 countsByYear W20482859122017 @default.
• W2048285912 countsByYear W20482859122018 @default.
• W2048285912 countsByYear W20482859122019 @default.
• W2048285912 countsByYear W20482859122020 @default.
• W2048285912 countsByYear W20482859122021 @default.
• W2048285912 countsByYear W20482859122022 @default.
• W2048285912 countsByYear W20482859122023 @default.
• W2048285912 crossrefType "journal-article" @default.
• W2048285912 hasAuthorship W2048285912A5000979147 @default.
• W2048285912 hasAuthorship W2048285912A5013254367 @default.
• W2048285912 hasAuthorship W2048285912A5013987568 @default.
• W2048285912 hasAuthorship W2048285912A5018249388 @default.
• W2048285912 hasAuthorship W2048285912A5032363862 @default.
• W2048285912 hasAuthorship W2048285912A5036820615 @default.
• W2048285912 hasAuthorship W2048285912A5040979952 @default.
• W2048285912 hasAuthorship W2048285912A5053879558 @default.
• W2048285912 hasAuthorship W2048285912A5078781359 @default.
• W2048285912 hasAuthorship W2048285912A5088055918 @default.
• W2048285912 hasAuthorship W2048285912A5089833045 @default.
• W2048285912 hasBestOaLocation W20482859122 @default.
• W2048285912 hasConcept C10138342 @default.
• W2048285912 hasConcept C150903083 @default.
• W2048285912 hasConcept C153911025 @default.
• W2048285912 hasConcept C162324750 @default.
• W2048285912 hasConcept C170493617 @default.
• W2048285912 hasConcept C178790620 @default.
• W2048285912 hasConcept C185592680 @default.
• W2048285912 hasConcept C195687474 @default.
• W2048285912 hasConcept C197404232 @default.
• W2048285912 hasConcept C202751555 @default.
• W2048285912 hasConcept C207001950 @default.
• W2048285912 hasConcept C2777807558 @default.

• next